Publication & Citation Trends
Publications
6 total
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials PDF
Cited by 340
OpenAlex
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies OA
Cited by 18
Semantic Scholar
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial OA
Cited by 42
Semantic Scholar
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. OA
Cited by 56
Semantic Scholar
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Cited by 216
Semantic Scholar
Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure
Cited by 10
Semantic Scholar
Fostamatinib, a Syk‐Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
Cited by 22
Semantic Scholar
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. OA
Cited by 401
Semantic Scholar
Research Topics
Hematopoietic Stem Cell Transplantation
(2)
Platelet Disorders and Treatments
(2)
Acute Lymphoblastic Leukemia research
(2)
Blood groups and transfusion
(2)
Asthma and respiratory diseases
(1)
Affiliations
Memorial Sloan Kettering Cancer Center
Rigel (United States)
Sunesis (United States)